Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ajinomoto to study nateglinide in combination with DPP IV inhibitor

Oct. 10, 2012

European Commission approves Bayer Healthcare's Flexyess

Oct. 10, 2012

FDA reclassifies clinical hold status for Proellex clinical program

Oct. 10, 2012

Asterion patents new fusion proteins for GH disorders

Oct. 10, 2012

Taisho Pharmaceutical divulges novel MGAT2 inhibitors

Oct. 10, 2012

Astellas Pharma discloses novel VAP-1 inhibitors

Oct. 10, 2012

Novel agents for diabetes prepared by Danish group

Oct. 8, 2012

Patient recruitment completed in two phase III Afrezza trials

Oct. 8, 2012

Empagliflozin has beneficial effects on blood pressure

Oct. 8, 2012

ITCA-650 evaluated in phase II dose-finding study

Oct. 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...